The place of polymer prodrugs in cancer therapy

Bibliography

• RINGSDORF H: Structure and properties of pharmaco-logically active polymers. J. Polym. ScL Polym. Symp. (1975) 51:135–153.
   Google Scholar
• MATSUMARA Y, MAEDA H: A new concept for macro molecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumu-lation of proteins and antitumor agent SMANCS. Cancer Res. (1986) 46:6387–6392.
   PubMed Web of Science ®Google Scholar
• IWAI K, MAEDA H, KONNO T: Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and x-ray image. Cancer Res. (1984) 44:2115–2121.
   PubMed Web of Science ®Google Scholar
• Mayersen HS, Thomas CC (Eds.), Springfield, Illinois, USA (1963):89–126.
   Google Scholar
• MAEDA H, MATSUMURA Y: Tumoritropic and lympho-tropic principles of macromolecules. CRC Crit. Rev. Ther. Drug. Carrier Sys. (1989) 6:193–210.
   PubMed Web of Science ®Google Scholar
• COUVREUR P, VAUTIER: Polyalkycyanoacrylate nanoparticles as drug carriers: present state and prospectives. J. Contr. Release (1991) 17:187–198.
   Web of Science ®Google Scholar
• KOPECEK J, BAZILOVA H: HPMA -1. Radical polymeri-zation and co-polymerization. Eur. Polymer J. (1973) 9:7–14.
   Web of Science ®Google Scholar
• CASSIDY J, DUNCAN R, MORRISON GJ, et al: Activity ofN-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol (1989) 38:875–879.
   PubMed Web of Science ®Google Scholar
• SEYMOUR LW, ULBRICH K, STEYGER PS, et al.: Tumourtropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcuta-neous murine B16/F10 melanoma. Br. J Cancer (1994) 70:636–641.
   PubMed Web of Science ®Google Scholar
• DUNCAN R, KOPECKOVA-REJMANOVA P, STROHALM J, et al.: Anticancer agents coupled to [ N-(2-hydroxypropyl)methacrylamide] copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer (1987) 55:165–174.
   PubMed Web of Science ®Google Scholar
• DUNCAN R, CABLE HC, LLOYD JB, REJMANOVA P, KOPECEK J: Degradation of side chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiolproteinases. Biosci. Rep. (1982) 2:1041–1046.
   PubMed Web of Science ®Google Scholar
• MINKO T, KOPECKOVA P, POZHAROV V, KOPECEK J:HPMA copolymers bound adriamycin overcomes MDRI gene encoded resistance in a human ovarian carcinoma cell line. J. Controlled Release (1998) 54:223–233.
   PubMed Web of Science ®Google Scholar
• VASEY P, KAYE SB, MORRISON R, et al.: Phase I clinical and pharmacokinetic study of PK 1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. (1999) 5:83–94.
   PubMed Web of Science ®Google Scholar
• ••Phase I study demonstrating proof of principle of HPMApolymer prodrug conjugates (PK1).
   Google Scholar
• VON HOFF DD, LAYARD MW, BASA P, et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. (1979) 91:710–717.
   PubMed Web of Science ®Google Scholar
• DeVita VT, Hellman S, Rosenberg SA (Eds.), Lippincott-Raven, Philadelphia, USA (1997):452–467.
   Google Scholar
• SEYMOUR LW, ULBRICH K, WEDGE SR, HUME IC, STROHALM J, DUNCAN R: N-(2-hydroxypropy1)-methacrylamide copolymers targeted to the hepato-cyte galactose-receptor-pharmacokinetics in DBA2 mice. Br. J. Cancer (1991) 6:859–866.
   Google Scholar
• FERRY DR, JULYAN P, SEYMOUR LW, et al: Phase I trial ofliver targeted HPMA copolymer doxorubicin PK2, pharmacokinetics, 123 I-SPECT imaging and activity in hepatoma. 35th ASCO Meeting Atlanta, USA (1999). Abstract 628.
   Google Scholar
• •First report of the further development of a HPMA polymer-drug conjugate (PK2) with more selective drug delivery.
   Google Scholar
• GIANASI E, WASIL M, EVAGOROU EG, et al.: HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer (1999) 35:994–1002.
   Google Scholar
• OMEL YANENKO V, GENTRY C, KOPECKOVA P, et al.:HPMA cop o lym er -an tican cer drug-OV-TLI 6 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J Cancer (1998) 75:600–608.
   PubMed Web of Science ®Google Scholar
• NANNAN PANDAY VR, MEERUM TERWOGT JM, TEN BOKKEL HUININK WW, et al.: Phase I and pharmacol-ogical study of water soluble polymer-conjugated paclitaxel (PNU 166945) administered as a 1-hour infusion in patients with advanced solid tumours. 34th ASCO Meeting. Los Angeles, USA (1998). Abstract 742.
   Google Scholar
• DE BONO JS, BISSETT D, TWELVES C, et al.: Phase Ipharmacokinetic (PK) study of MAG-CPT (PNU 166148), a polymeric derivative of camptothecin (CPT). 35th ASCO Meeting New Orleans, USA (2000). Abstract 771.
   Google Scholar
• Maeda H, Edo K, Ishida N (Eds.), Springer-Verlag, Tokyo, Japan (1997):129–152.
   Google Scholar
• Maeda H, Edo K, Ishida N. (Eds.), Springer-Verlag, Tokyo, Japan (1997):205–226.
   Google Scholar
• Maeda H, Edo K, Ishida N (Eds.), Springer-Verlag, Tokyo, Japan (1997):227–267.
   Google Scholar
• IWAI K, MAEDA H, KONNO T: Use of oily contrast medium for selective drug targeting to tumour: enhanced therapeutic effect and x-ray image. Cancer Res. (1984) 44:2115–2121.
   PubMed Web of Science ®Google Scholar
• SEYMOUR LW, OLLIFF SP, POOLE C, et al.: Anovel dosage approach for the evaluation of SMANCS [p o ly-(styr en e-co -m aleyl-h alf-N-butylate)-n eo car z-inostatin] in the treatment of primary hepatocellular carcinoma. Int. j Oncol (1998) 12(6)1217–1223.
   PubMedGoogle Scholar
• ROSENBERG SA, LOTZE MT, YANG JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. (1989) 210:474–485.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose interleukin-2. JAMA (1994) 271:907–913.
   PubMed Web of Science ®Google Scholar
• ABUCHOWSKI A, MCCOY JR, PALCZUK NS, et al: Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. j Biol. Chem. (1977) 252:3582–3586.
   PubMed Web of Science ®Google Scholar
• MEYERS FJ, PARADISE C, SCUDDER MD, et al.: A Phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clin. Pharmacol Ther. (1991) 49:307–313.
   PubMed Web of Science ®Google Scholar
• LI C, YU D, INOUE T, et al: Synthesis and evaluation of water soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. AntiCancer Drugs (1996) 7(6):642–648.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, HOLMES R, LERMER S, HO DH: L-Asparag-inase and PEG asparaginase -past, present and future. Leuk. Lymphoma (1993) 10:153–157.
   PubMedGoogle Scholar
• CONOVER CD, GREENWALD RB, PENDRI A, et al.: Camp to thecin delivery systems: enhanced efficacy and tumour accumulation of campothecin followingits conjugation to polyethylene glycol via a glycine linker. Cancer Chem other. Pharmacol. (1998) 42:407–414.
   PubMed Web of Science ®Google Scholar
• OCHOA L, TOLHER AW, RIZZO J, et al.: A Phase I study ofPEG-camptothecin (PEG-CPT) in patients with advanced solid tumours: a novel formulation for an insoluble but active agent. 35th ASCO Meeting. New Orleans, USA (2000). Abstract 770.
   Google Scholar
• CONOVER CD, BOROWSKI V, HSU J, SHUM KL: PEG prodrugs of cytosine arabinoside II: in vivo anti-tumour activity. AACR Meeting. USA (2000). Abstract 3330.
   Google Scholar
• YUAN F, LEUNIG M, HUANG SK, et al.: Microvascular permeability and interstitial penetration of sterically stabilised (stealth) liposomes in a human tumour xenograft. Cancer Res. (1994) 54:3352–3356.
   PubMed Web of Science ®Google Scholar
• FORSSEN EA, COULTER DM, PROFFITT RT: Selective in vivo localisation of daunorubicin small unilamallar vesicles in solid tumours. Cancer Res. (1992) 52:3255–3261.
   PubMed Web of Science ®Google Scholar